skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features

Review

(2762) Views  (528) Full article downloads

Authors: Angelo Antonini, Giovanni Abbruzzese, Paolo Barone, Ubaldo Bonuccelli, Leonardo Lopiano, et al

Published Date March 2008 Volume 2008:4(1) Pages 1 - 9
DOI: http://dx.doi.org/10.2147/NDT.S2404

Angelo Antonini1, Giovanni Abbruzzese2, Paolo Barone3, Ubaldo Bonuccelli4, Leonardo Lopiano5, Marco Onofrj6, Mario Zappia7, Aldo Quattrone8

1Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy; 2Movement Disorder Unit, Neurology, University of Genoa, Genoa, Italy; 3Dipartimento di Scienze Neurologiche, Università di Napoli Federico II, Naples, Italy; 4University of Pisa, Department of Neuroscience, Pisa, Italy; 5Department of Neuroscience, University of Turin, Turin, Italy; 6Department of Oncology and Neuroscience, University G D’Annunzio, G D’Annunzio Foundation CESI, Chieti-Pescara, Italy; 7Department of Neurosciences, University of Catania; 8Institute of Neurology, University “Magna Græcia,” Catanzaro, Italy

Abstract: Levodopa is the most effective treatment in Parkinson’s disease and the association with COMT inhibitors widens its plasma bioavailability and effectiveness. Tolcapone is a potent COMT inhibitor whose utilization in PD is limited due to safety concerns on liver toxicity. However, recent data indicate that if liver function is actively monitored, tolerability is no worse than other currently available therapies. By contrast, administration of tolcapone is associated with significant clinical improvement and benefit involves also non-motor features. In this review we discuss the rationale for the use of tolcapone in association with levodopa and other treatments in PD, and we provide an indirect comparison of current strategies to reduce “off” time. We propose that future guidelines include a trial with tolcapone in all PD patients who continue to complain about motor fluctuations despite treatment with entacapone and/or MAO-B inhibitors. Moreover, we suggest that tolcapone should be considered before surgical or infusional strategies are applied.

Keywords: Parkinson’s disease, levodopa, motor fluctuations, COMT inhibitors, tolcapone






 

Other articles by Professor Angelo Antonini



Readers of this article also read:

Health literacy and health seeking behavior among older men in a middle-income nation
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Wearing facemasks when performing lumbar punctures: a snapshot of current practice amongst trainee doctors
Erratum - Intracellular heavy metal nanoparticle storage
What is infidelity? Perceptions based on biological sex and personality
Remembering and forgetting: directed forgetting effect in obsessive-compulsive disorder
TiO2 micro-nano-hybrid surface to alleviate biological aging of UV-photofunctionalized titanium
Risk factor investigation for cardiovascular health through WHO STEPS approach in Ardabil, Iran
Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease